Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Buys 33,726 Shares of Stock

October 1, 2026 by InsiderTrades.com

Key Points

Director Bros. Advisors LP Baker bought 33,726 Kodiak Sciences shares at an average price of $85.05, investing approximately $2.87 million. Including several purchases the previous day, Baker acquired roughly 1.94 million shares for about $157 million.
Kodiak shares opened at $94.80, near their 12-month high of $98.80, while analysts maintained a generally positive outlook. Six analysts rate the stock Buy, with an average price target of $100.43.
The company still faces significant risks: it reported a quarterly loss of $1.05 per share, has no current revenue, continues to burn cash, and may need future financing despite enthusiasm surrounding positive Phase 3 retinal-disease trial results.

Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) Director Bros. Advisors Lp Baker bought 33,726 shares of the stock in a transaction that occurred on Tuesday, September 29th. The shares were purchased at an average cost of $85.05 per share, for a total transaction of $2,868,396.30. Following the completion of the acquisition, the director owned 20,191,214 shares of the company's stock, valued at $1,717,262,750.70. This trade represents a 0.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Bros. Advisors Lp Baker also recently made the following trade(s):

On Monday, September 28th, Bros. Advisors Lp Baker purchased 807,840 shares of Kodiak Sciences stock. The stock was acquired at an average price of $72.57 per share, for a total transaction of $58,624,948.80.
On Monday, September 28th, Bros. Advisors Lp Baker purchased 418,323 shares of Kodiak Sciences stock. The stock was acquired at an average cost of $83.58 per share, with a total value of $34,963,436.34.
On Monday, September 28th, Bros. Advisors Lp Baker acquired 681,866 shares of Kodiak Sciences stock. The shares were acquired at an average price of $88.77 per share, with a total value of $60,529,244.82.

Kodiak Sciences Trading Up 4.0%

NASDAQ:KOD opened at $94.80 on Thursday. The company has a 50-day moving average of $41.32 and a 200-day moving average of $38.77. The firm has a market cap of $5.96 billion, a price-to-earnings ratio of -22.63 and a beta of 2.18. Kodiak Sciences Inc. has a twelve month low of $10.94 and a twelve month high of $98.80.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09). On average, research analysts forecast that Kodiak Sciences Inc. will post -3.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KOD. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kodiak Sciences in a research report on Friday, July 10th. JPMorgan Chase & Co. lifted their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Jefferies Financial Group reaffirmed a "buy" rating and set a $112.00 target price on shares of Kodiak Sciences in a research report on Monday. Wall Street Zen downgraded Kodiak Sciences from a "sell" rating to a "strong sell" rating in a report on Saturday, September 26th. Finally, HC Wainwright increased their price target on Kodiak Sciences from $58.00 to $96.00 and gave the company a "buy" rating in a research report on Monday. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Kodiak Sciences currently has an average rating of "Moderate Buy" and an average price target of $100.43.

Check Out Our Latest Stock Analysis on KOD

Kodiak Sciences News Summary

Here are the key news stories impacting Kodiak Sciences this week:

Positive Sentiment: Strong Phase 3 results drive investor enthusiasm. Zenkuda and KSI-501 reportedly achieved their primary goals in the DAYBREAK study for wet age-related macular degeneration, meeting key endpoints against Eylea. Kodiak is advancing Zenkuda toward a biologics license application (BLA), creating a potential path toward regulatory review in a large retinal-drug market. Zenkuda positive wet AMD data article
Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm lifted its FY2029 EPS forecast to $1.76 from $0.18 and its FY2030 forecast to $5.81 from $3.04. It maintained a Buy rating and a $96 price target, while projecting a transition from losses in FY2027 and FY2028 to profitability in FY2029. Kodiak Sciences analyst estimates
Positive Sentiment: Insider purchases provide a confidence signal. Director Bros. Advisors LP Baker reported multiple purchases totaling roughly 1.94 million shares for approximately $157 million across September 28–29. The buying materially increased the director’s already substantial ownership stake. SEC insider ownership filing
Neutral Sentiment: Near-term analyst revisions were mixed. HC Wainwright slightly reduced its FY2027 loss estimate to $3.36 per share from $3.27, but improved forecasts for later years as it incorporated the potential impact of Zenkuda.
Negative Sentiment: Investors face substantial execution and financing risks. Kodiak has no current revenue and continues to burn cash, making a future share offering possible. Unusually high put-option buying also suggests some traders are positioning for volatility or a pullback after the dramatic rally. Kodiak valuation and financing risks article

Institutional Trading of Kodiak Sciences

Several hedge funds and other institutional investors have recently modified their holdings of KOD. V Square Quantitative Management LLC purchased a new position in Kodiak Sciences in the first quarter valued at about $26,000. Westfuller Advisors LLC acquired a new position in Kodiak Sciences in the 1st quarter worth about $26,000. EverSource Wealth Advisors LLC raised its stake in shares of Kodiak Sciences by 1,221.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company's stock worth $28,000 after purchasing an additional 916 shares in the last quarter. KBC Group NV purchased a new stake in shares of Kodiak Sciences during the 1st quarter worth about $39,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Kodiak Sciences during the 2nd quarter valued at about $228,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile

(Get Free Report)

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company's research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.